Navigation Links
CD86 Found On B Cells Boosts Immune Response

According to researchers from Ohio state university it was found that CD86 present on the B lymphocytes increase the antibody produced by the lymphocyte.//

CD86 is a protein and it used to stimulate other immune cells such as T cells to respond to a stimulus or antigen. The study by Ohio State University scientists is published in a recent issue of The Journal of Immunology. The research, conducted in mouse cells, provides important details about how B cells make antibodies in response to infections.

Antibodies are proteins that attach to viruses, bacteria and other infectious agents to disable them. The findings could lead to new ways of boosting the immune response against bacteria that cause pneumonia, a leading killer of people with weakened immunity such as cancer and HIV/AIDS, and of controlling autoimmune diseases.

‘Our findings describe a previously unknown signaling pathway in B cells that helps regulate antibody production,’ says principal investigator Virginia M. Sanders, professor in department of molecular virology, immunology and medical genetics and an OSU Comprehensive Cancer Center researcher. ‘The findings show that CD86 actually sends signals into the B cell itself, causing it to make a greater amount of antibody. If this is verified in human cells, they could be clinically important.’ B cells begin making antibodies after they detect bits of bacteria, viruses or cancer cells in the body. But first the cells must be activated by contact with T cells in lymph nodes. During that interaction, CD86 proteins on the B cells fit like a key into a protein on the T cells called CD28.

If these and other proteins on the two cells also fit together properly, the T cell releases a substance that causes the B cell to proliferate and churn out antibodies against the antigen. But there was no indication that the interaction between the CD86 protein and a T cell had any influence on the B cell itself. Earlier work by San ders and her laboratory, however, strongly suggest the CD86 protein did alter the behavior of the B cell. She and her research team showed that B cells produce much more antibody when CD86 interacts with its T-cell protein than occurs when that interaction is missing. For this study, Sanders and Kin used two groups of laboratory-grown mouse B cells, which are easier to grow than human B cells. Then they stimulated one group of B cells with all the signals provided by T cells, including the interaction of CD86 and its T-cell protein.

The second group of B cells received all the T-cell signals, except the one for CD86. The researchers then compared the two groups for changes in antibody levels and changes in the signaling molecules associated with antibody production inside the B cells. This enabled the scientists to trace the chemical changes that begin with CD86 and run through the B cell and the making of antibodies. ‘We showed for the first time what signaling molecules are activated inside B cells when CD86 is stimulated,’ says first author Nicholas W. Kin, a graduate research associate in Sanders' laboratory. We also found that the signals converge on a protein that controls antibody production. ‘This is another piece in the complex puzzle of how the immune system works and how it might be manipulated to fight cancer and autoimmune diseases,’ Kin adds.

Source: Eurealert
'"/>




Related medicine news :

1. Fluoride Found Effective in Osteoporosis
2. Implantable Contact Lens Found Safe and Effective
3. Cancer hazard Found With Animal-Based Nutrients
4. Processed Meat, Diabetes connection Found
5. Night Time Aspirin Regimen Found to Reduce Blood Pressure
6. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
7. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
8. Preventive Therapies Found to be More Effective in Managing Migraines
9. Common Cold Found to Fight Cancer
10. Circumcision Found To Prevent HIV Spread
11. Drug Found To Reduce The Transmission Of Herpes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: